In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Dawning of the Life Sciences Defense Industry

Executive Summary

To former SmithKline Beecham R&D head George Poste, the engagement of government and industry to combat biothreats is not a matter of choice or even enlightened self-interest, but an imperative. For the past five years, he has been participating in the activities of the US Defense Science Board and engaging industry on the subject of bioterrorism and the broader issue of the spread of infectious disease. In an extensive interview with IN VIVO, he argues for creation of a life sciences defense industry--a closer and deeper relationship between government and the private sector that will mean a loss of innocence for the historically open life sciences culture. And he says government must address the lack of adequate incentives, which has discouraged private-sector participation in the past.

You may also be interested in...

Intra-Cellular Therapies Inc.

Built on technology from the lab of Nobel laureate Paul Greengard, PhD, Intra-Cellular Therapies Inc. aims to develop small-molecule compounds that modify intracellular responses to endogenous neurotransmitters as therapeutics for Parkinson's disease, depression, schizophrenia and other CNS disorders.

For 2001, A Top Eleven List

2001 was a mixed year for health-care manufacturers, characterized by real advances in cardiac device therapies, the maturing of the biotech and generics sectors, and the continued embattlement of Big Pharma. Here's the staff of IN VIVO's list of the most important trends.

Viatris And Biocon Launch Bevacizumab Biosimilar In Canada

Viatris and Biocon have introduced their Abevmy biosimilar bevacizumab version of Avastin in Canada. Marking the third oncology biosimilar – and the fourth biosimilar overall – to be launched by Viatris in Canada, the product will face multiple other approved bevacizumab rivals in the market.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts